Trade Eli Lilly ^LLY

Wealth Enhancement Trust Services Inc. Sells 579 Shares of Eli Lilly and Company $LLY - Markets Daily

Wealth Enhancement Trust Services Inc. Reduces Stock Holdings in Eli Lilly and Company $LLY - Zolmax

Canandaigua National Trust Co of Florida Acquires 16,555 Shares of Eli Lilly and Company $LLY - Zolmax

16,555 Shares in Eli Lilly and Company $LLY Bought by Canandaigua National Trust Co of Florida - Markets Daily

Eli Lilly and Company $LLY Stock Sold by Bank & Trust Co - Markets Daily

Lake Hills Wealth Management LLC Purchases New Holdings in Eli Lilly and Company $LLY

Eli Lilly and Company $LLY Shares Sold by Bank & Trust Co

Eli Lilly and Company $LLY Stock Sold by American National Bank & Trust - Markets Daily

LLY Maintained by Morgan Stanley -- Price Target Raised to $1430

Eli Lilly and Company (NYSE:LLY) Stock Jumps 2.5% - Should You Buy? - Daily Political

American National Bank & Trust Sells 532 Shares of Eli Lilly and Company $LLY - Stock Observer

Lilly's Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound

Top Healthcare Stocks To Watch Now - October 7th - Daily Political

Eli Lilly and Company (NYSE:LLY) and Fortress Biotech (NASDAQ:FBIO) Critical Review - Markets Daily

Eli Lilly and Company $LLY Stake Raised by RVW Wealth LLC - Zolmax

Eli Lilly and Company $LLY Position Increased by RVW Wealth LLC - Markets Daily

Congress Asset Management Co. Buys 1,454 Shares of Eli Lilly and Company $LLY

Eli Lilly and Company (NYSE:LLY) Stock Jumps 1.3% - What's Next?

Promising Healthcare Stocks To Watch Now - October 6th - Stock Observer

insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab | Morningstar

Top Pharmaceutical Stocks To Follow Now - October 5th - Markets Daily

Eli Lilly and Company $LLY Shares Acquired by Park National Corp OH

Eli Lilly and Company $LLY Stock Sold by Eastern Bank

CapWealth Advisors LLC Acquires 962 Shares of Eli Lilly and Company $LLY

Top Pharmaceutical Stocks To Follow Now - October 5th - Stock Observer

Eli Lilly Expands Gate Bioscience Molecular Gates Collaboration

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions | Morningstar

Best Pharmaceutical Stocks To Add to Your Watchlist - October 4th - Stock Observer

Eli Lilly launches 'Nujoom Al Ghad' to build next generation of Emirati talent in healthcare

Eli Lilly's Valuation Has Changed. Here's What Investors Need to Know

Pharmaceutical Stocks To Watch Now - October 3rd - Zolmax

FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL

Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories

6,930 Eli Lilly and Company $LLY Shares Sold by CX Institutional

Case: Patents/Procedure (Fed. Cir.)

Lilly, Novo bet on amylin obesity drugs after GLP-1s

"Patient-centric innovation must be central mission of life sciences industry": JP Nadda at BLSA awards

Coastline Trust Co Sells 1,123 Shares of Eli Lilly and Company $LLY

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment | Morningstar

Best Pharmaceutical Stocks To Follow Today - October 1st - Stock Observer

Lilly Reports Foundayo Data Showing Lower Predicted Diabetes And Cardiovascular Risk

Oral GLP-1 Drugs: Novo Nordisk, Eli Lilly Eye India Launch In 2027 | Pharma Stocks In Focus

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials With Ely Lilly | Morningstar

LLY: Pipeline Promise Remains, Pricing And Legal Risks Now Drive The Bear Case

Lilly's oral GLP-1, Foundayo , was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease | INN

Lilly's Foundayo Shows Cardiovascular Safety, Sustained A1C And Weight Benefits In ACHIEVE-4

Lilly's Foundayo Demonstrates Cardiovascular Safety In Landmark Diabetes Study

Foghorn cuts staff 40% as Lilly terminates SMARCA2 deal | BioWorld

Rose-Hulman Hosts Fall Career Fair With hundreds Employers

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study | Morningstar

Eli Lilly and Company (NYSE:LLY) Stock Falls 1.9% - What's Next?

Promising Pharmaceutical Stocks Worth Watching - September 30th

Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial

Lilly's EBGLYSS Shows Rapid Skin Clearance And Symptom Relief In Phase 3b Study

New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis | Morningstar

Eli Lilly and Company (NYSE: LLY) EloraTZP Adds Weight Loss and More Dropouts - Stock Observer

Lilly's Retatrutide Drives Significant Weight Loss And A1C Improvement In Phase 3 Diabetes Study

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes | Morningstar

Eli Lilly (LLY) Stock: Foundayo Outpaces Novo's Ozempic in Latest Diabetes Data

Promising Healthcare Stocks To Follow Today - September 29th - Stock Observer

Lilly Reports Orforglipron Results Versus Oral Semaglutide 25 mg in Indirect Analysis

Lilly's Zepbound was associated with more weight loss than Wegovy HD in a new indirect treatment comparison | INN

Lilly's Foundayo Tops Oral Semaglutide In New Diabetes Analysis

What Could Eli Lilly (LLY) New Cancer Win And Deal Shift Mean?

Global Overseas Giants Rush to Acquire Upstream Medical Isotopes - Why Chinese Nuclear Pharmaceutical Enterprises Are Not Rushing?

Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political

Alcohol Use Disorder Market Outlook Shows Significant Expansion Across the 7MM Through 2036 | ABNewswire

Eli Lilly and Company (NYSE:LLY) Given New $1,500.00 Price Target at JPMorgan Chase & Co. - Daily Political

Promising Pharmaceutical Stocks To Research - September 28th - Zolmax

Can Roche's Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?

Healthcare Stocks To Add to Your Watchlist - September 28th - Zolmax

Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,500.00

Bharat Life Sciences Award 2026 Innovation Summit to explore India's next phase of life sciences growth

Eli Lilly and Company (LLY) is Expanding Beyond its Biggest Growth Drivers. Can it Sustain the Momentum?

Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations

China's InnoCare inks $3.5 B deal with Eli Lilly to develop new medicines

A New Wave of Senior Patients Could Extend Lilly's GLP-1 Growth Story

Lilly's Oral GLP-1 Push Gains Momentum. Can Foundayo Become its Next Growth Engine?

Promising Pharmaceutical Stocks To Consider - September 27th - Zolmax

FDA Expands Lilly's Olumiant Approval To Adolescents With Severe Alopecia Areata

Foundayo's Early Growth Is Raising Lilly (LLY)'s Revenue Expectations. But Can It Outrun Pricing Pressure?

Eli Lilly and Company (NYSE:LLY) Shares Climb 2.8% - What's Next? - Zolmax

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?

FDA approves Lilly's Olumiant for pediatric patients 12 years of age and older with severe alopecia areata | INN

Why GLP-1 drugs are under fresh scrutiny over a rare eye condition linked to vision loss

Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study

Analyzing Prestige Consumer Healthcare (NYSE:PBH) & Eli Lilly and Company (NYSE:LLY)

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Jury awards $90M to Nektar in Lilly dispute over rezpeg | BioWorld

Eli Lilly and Company (NYSE:LLY) Stock Jumps 2.8% - Still a Buy?

Why we like Starbucks' latest turnaround move - plus, two more wins for Eli Lilly

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Week ahead: Apple leads big tech earnings, UK Budget and Nonfarm Payrolls

Week ahead: RBA meeting, Uber earnings, and PMIs

Week ahead: Apple earnings land as Fed seen holding rates

Week ahead: Earnings season climax

Week ahead: Fed, Bank of England seen on pause; Apple earnings

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk